Tower Research Capital (TRC)’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Tower Research Capital (TRC)’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-496	Closed	-$8.24K	–	5719
2024 Q1	$8.24K	Buy	+496	New	+$7.64K	﹤0.01%	4056
2021 Q4	–	Sell	-16	Closed	–	–	6178
2021 Q3	$0	Buy	+16	New	+$483	﹤0.01%	5803
2020 Q4	–	Sell	-35	Closed	-$1K	–	5146
2020 Q3	$1K	Buy	+35	New	+$936	﹤0.01%	4682
2020 Q2	–	Sell	-519	Closed	-$10K	–	4760
2020 Q1	$10K	Buy	+519	New	+$11.2K	﹤0.01%	2012
2019 Q4	–	Sell	-134	Closed	-$3K	–	3636
2019 Q3	$3K	Buy	134 +47	+54%	+$954	﹤0.01%	3530
2019 Q2	$2K	Buy	+87	New	+$1.79K	﹤0.01%	3245
2019 Q1	–	Sell	-100	Closed	-$2K	–	3841
2018 Q4	$2K	Buy	+100	New	+$2.08K	﹤0.01%	3323
2016 Q3	–	Sell	-36	Closed	-$1K	–	3723
2016 Q2	$1K	Sell	36 -24	-40%	-$548	﹤0.01%	4131
2016 Q1	$1K	Sell	60 -40	-40%	-$854	﹤0.01%	3655
2015 Q4	$3K	Buy	+100	New	+$2.88K	﹤0.01%	3405

Other funds holding CNCR

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

RIA

Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SWA

SOA Wealth Advisors New York $595M AUM 25.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s CNCR Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2024, closing a stake of 496 shares — an estimated $8.24K sold.

Tower Research Capital (TRC) first reported a position in CNCR in Q4 2015 and held it in 10 quarters. The position peaked at $10K in Q1 2020. 13 funds tracked by Wall St. Rank hold CNCR as of Q2 2024.

Tower Research Capital (TRC) reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2024 after selling out during the quarter.
Tower Research Capital (TRC) sold 496 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2024, an estimated $8.24K.
Tower Research Capital (TRC) first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2015 and held it in 10 quarters.
Tower Research Capital (TRC)'s ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $10K in Q1 2020.
13 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.